129 related articles for article (PubMed ID: 3754266)
1. Tentative disk diffusion susceptibility interpretive criteria for BMY-28142, a new cephalosporin.
Fuchs PC; Jones RN; Barry AL; Thornsberry C
J Clin Microbiol; 1986 Mar; 23(3):634-6. PubMed ID: 3754266
[TBL] [Abstract][Full Text] [Related]
2. In vitro antibacterial spectrum of E1040 compared with those of cefpirome and ceftazidime and disk diffusion interpretive criteria for E1040.
Fuchs PC; Jones RN; Barry AL
Antimicrob Agents Chemother; 1990 May; 34(5):914-7. PubMed ID: 2193626
[TBL] [Abstract][Full Text] [Related]
3. Tentative disk diffusion susceptibility interpretive criteria for pefloxacin.
Fuchs PC; Barry AL; Jones RN; Thornsberry C
J Clin Microbiol; 1986 Sep; 24(3):448-50. PubMed ID: 3463566
[TBL] [Abstract][Full Text] [Related]
4. Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing.
Fuchs PC; Barry AL; Thornsberry C; Jones RN; Gavan TL; Gerlach EH; Sommers HM
Antimicrob Agents Chemother; 1980 Jul; 18(1):88-93. PubMed ID: 6251750
[TBL] [Abstract][Full Text] [Related]
5. Disk diffusion susceptibility testing and broth microdilution quality control guidelines for BMY-28100, a new orally administered cephalosporin.
Jones RN; Barry AL
J Clin Microbiol; 1987 Nov; 25(11):2211-3. PubMed ID: 3121667
[TBL] [Abstract][Full Text] [Related]
6. Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing.
Ayers LW; Jones RN; Barry AL; Thornsberry C; Fuchs PC; Gavan TL; Gerlach EH; Sommers HM
Antimicrob Agents Chemother; 1982 Nov; 22(5):859-77. PubMed ID: 6983862
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.
Tsuji A; Maniatis A; Bertram MA; Young LS
Antimicrob Agents Chemother; 1985 Apr; 27(4):515-9. PubMed ID: 3839120
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.
Fuchs PC; Jones RN; Barry AL; Thornsberry C
Antimicrob Agents Chemother; 1985 May; 27(5):679-82. PubMed ID: 3893316
[TBL] [Abstract][Full Text] [Related]
9. Cefoperazone disk diffusion susceptibility test: confirmation of the tentative interpretive criteria, Pseudomonas aeruginosa cross-resistance, and determination of quality control performance limits.
Jones RN; Gavan TL; Barry AL; Thornsberry C; Gibbs DL
J Clin Microbiol; 1982 May; 15(5):777-86. PubMed ID: 6212596
[TBL] [Abstract][Full Text] [Related]
10. In-vitro activity of BMY 28142, a new aminothiazolyl cephalosporin.
Steele JC; Edwards BH; Rissing JP
J Antimicrob Chemother; 1985 Oct; 16(4):463-8. PubMed ID: 3840799
[TBL] [Abstract][Full Text] [Related]
11. Cefixime disk susceptibility test criteria.
Fuchs PC; Barry AL; Jones RN
J Clin Microbiol; 1986 Oct; 24(4):647-9. PubMed ID: 3771755
[TBL] [Abstract][Full Text] [Related]
12. Cefoperazone: regression analysis, disk content, and disk susceptibility testing considerations.
Wright DN; Welch DF; Saxon BA; Clark SJ; Matsen JM
Antimicrob Agents Chemother; 1982 Sep; 22(3):493-8. PubMed ID: 6215895
[TBL] [Abstract][Full Text] [Related]
13. Disk diffusion susceptibility test interpretive criteria for GR69153, a new catechol-substituted cephalosporin.
Jones RN; Erwin ME
J Clin Microbiol; 1991 Dec; 29(12):2890-2. PubMed ID: 1757568
[TBL] [Abstract][Full Text] [Related]
14. In vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin.
Vuye A; Pijck J
Antimicrob Agents Chemother; 1985 Apr; 27(4):574-7. PubMed ID: 3859244
[TBL] [Abstract][Full Text] [Related]
15. Preliminary disk diffusion susceptibility testing criteria for cefdaloxime (RU29246, HR-916 metabolite), a new orally administered cephalosporin.
Jones RN; Erwin ME
J Clin Microbiol; 1992 May; 30(5):1297-300. PubMed ID: 1583135
[TBL] [Abstract][Full Text] [Related]
16. Tentative interpretive standards for agar disk diffusion antimicrobial susceptibility testing of cefoperazone.
Thornsberry C; Barry AL; Jones RN; Baker CN; Badal RE
J Clin Microbiol; 1982 May; 15(5):769-76. PubMed ID: 6212595
[TBL] [Abstract][Full Text] [Related]
17. Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR810, a fourth-generation cephalosporin, in clinical microbiology laboratories.
Jones RN; Thornsberry C; Barry AL; Ayers L; Brown S; Daniel J; Fuchs PC; Gavan TL; Gerlach EH; Matsen JM
J Clin Microbiol; 1984 Sep; 20(3):409-12. PubMed ID: 6490826
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of Ro 19-5247 (T-2525) and interpretive criteria for disk diffusion susceptibility testing.
Beskid G; Fallat V; Siebelist J; Durkin JW; Lipschitz ER; McGarry DH
J Clin Microbiol; 1987 Jul; 25(7):1186-90. PubMed ID: 3112176
[TBL] [Abstract][Full Text] [Related]
19. Interpretive criteria for disk diffusion susceptibility testing of mupirocin, a topical antibiotic.
Fuchs PC; Jones RN; Barry AL
J Clin Microbiol; 1990 Mar; 28(3):608-9. PubMed ID: 2108997
[TBL] [Abstract][Full Text] [Related]
20. Mezlocillin: tentative interpretive standards for disk diffusion susceptibility testing.
Fuchs PC; Barry AL; Thornsberry C; Jones RN; Gerlack EH
Antimicrob Agents Chemother; 1981 Aug; 20(2):197-203. PubMed ID: 6456689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
